Anti-Estrogen Treatment for Post-Menopausal Women
Current guidelines recommend that postmenopausal women with early-stage, hormone receptor-positive breast cancer take one of the following:
• tamoxifen for 10 years;
• an aromatase inhibitor for five years;
• tamoxifen for five years, followed by an aromatase inhibitor for up to five years, for a total of 10 years of hormonal therapy; or
• tamoxifen for two to three years, followed by up to five years of an aromatase inhibitor, for a total of seven to eight years of hormonal therapy.